The world's first to use mRNA electroporation technology, enhancing product safety.
The world's first to use artificial intelligence to identify Target HLA-G, employing AI to identify critical tumor targets of human leukocyte antigen-G (HLA-G). The technology, “Allogeneic Non-viral Gene-Edited Multi-targeted Nanoantibody-CAR.BiTE-γδT Immune Cells”, demonstrated in preclinical animal experiments that over 90% of solid tumors were eradicated. It was published in top international medical journals and received approval from FDA in September 2023 for human clinical trials. The technology has been transferred to Ever Supreme Bio Technology Co..
Now...I admit I still could not find info about the starting date of phase 1 clinical trial and if PCa is one of the tumors that will be considered for the trial...gimme some time, I am asking some researchers in Taiwan to dig deeper.